appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Pfizer Ltd
PFIZER
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Pfizer Limited is a pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas.
Brands
Brands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Pfizer Nears Pre-Pandemic Levels: Is the Stock Ready to Bottom Out?
5 days ago•Investing.com
Pfizer - Expect A Fresh Wave Of New Launches: Systematix Initiates Coverage With A ‘Buy’
3 weeks ago•Bloomberg Quint
JB Chemicals gets USFDA nod to market generic medication
1 month ago•Economic Times
Recent EventsAll events
Updates
we re-submit herewith the unaudited financial results for the quarter ended June 30, 2023, in machine readable format as required by National Stock Exchange of India Limited. | Download
we re-submit herewith the unaudited financial results for the quarter ended June 30, 2023, in machine readable format as required by National Stock Exchange of India Limited. | Download
Cash Dividend
Final • Div/Share: ₹ 35
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant